Clinical trials: open to volunteers, sponsored by M.D. Anderson Cancer Center
Multiple Myeloma
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
To learn if isatuximab can help to control highrisk MM when given in combination with lenalidomide after an autologous stem cell transplantation (ASCT).
- Trial name
- NCT05776979
- Testing
- Isatuximab, lenalidomide
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Amputation
Target Muscle Re-innervation and Regenerative Peripheral Nerve Interfaces Alone and in Combination for the Treatment of Residual and Phantom Limb Pain in Cancer Patients Who Have Received an Amputation
This clinical trial evaluates two surgical techniques (targeted muscle re-innervation [TMR] and regenerative peripheral nerve interfaces [RPNI]) alone and in combination for the alleviation of chronic residual limb and phantom…
- Trial name
- NCT06840262
- Testing
- Questionnaire Administration, Regenerative Peripheral Nerve Interface Surgery, Targeted Muscle Reinnervation
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- M.D. Anderson Cancer Center
Sarcoma,Soft Tissue
PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study
This is a prospective, single-arm, open-label feasibility trial conducted at the MD Anderson Sarcoma Center and Cardio-Oncology Clinic.
- Trial name
- NCT07874828
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
To learn about the effectiveness of adding talazoparib to the standard of care treatment combination of androgen ablation therapy (hormone therapy, also known as ADT) and enzalutamide in patients with prostate cancer that has…
- Trial name
- NCT05873192
- Testing
- ADT, Enzalutamide, Talazoparib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Cancers, Fatigue
Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers
To find out if combining psychoeducational interventions (such as education, counseling, and self-managed therapies) with an open-label placebo can help to improve your quality of life better than either the psychoeducational…
- Trial name
- NCT06085716
- Testing
- Psychoeducational Intervention
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- M.D. Anderson Cancer Center
Communication Skills, Professionalism
Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits: a Randomized Controlled Trial (EHR Study #3)
To learn about how patients view a doctor's compassion, communication skills, and professionalism based on whether the doctor uses the Electronic Health Record (EHR) during a visit with a patient.
- Conditions
- Communication Skills, Professionalism, Randomized Controlled Trial, Perception
- Trial name
- NCT07089953
- Testing
- Questionnaire, Video
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- M.D. Anderson Cancer Center
Checkpoint Inhibitor, Pilot Study
Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study
To find out if taking a drug called infliximab (the "study drug") is safe and effective in reversing insulin dependence in CIADM.
- Conditions
- Checkpoint Inhibitor, Pilot Study, Diabetes Melletus
- Trial name
- NCT07257068
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Ropeginterferon, Alfa-2b
A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 Mutations
To find the recommended dose of ropeginterferon alfa-2b in combination with azacitidine in patients with newly diagnosed MDS/AML with TP53 mutations.
- Conditions
- Ropeginterferon, Alfa-2b, Azacitidine, MDS/AML
- Trial name
- NCT07646821
- Testing
- ropeginterferon alfa- 2b, Azacitidine (AZA)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Liver Tumors
Estimating The Rate Of Complete Ablation (A0) With The Use Of Biomechanical Deformable Image Registration
The goal of this research study is to find out if using an updated version of standard computer software (called RayStation) for confirming that thermal ablation treatment was able to destroy all tumor cells including a safety…
- Trial name
- NCT07877220
- Testing
- RayAblation
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer, Fallopian Tube Cancer
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence
- Trial name
- NCT05287451
- Testing
- RIsk-Reducing Salpingectomy (RRS), Risk-Reducing Oophorectomy-RRO, Risk-Reducing Salpingo-Oophorectomy-RRSO
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Dynamic Tumor Resistance, Metastatic Colorectal Cancer
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.
- Trial name
- NCT07318389
- Testing
- SOC (Standard of care), Bevacizumab, Cetuximab
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Anaplastic Thyroid Cancer
Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer
The goal of the trial is to improve this OS by 4 months (to 9.9 months) using the zanzalintinib + cemiplimab treatment combination.
- Trial name
- NCT07470489
- Testing
- Cemiplimab, Zanzalintinib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Evaluating, Intermittent Fasting
Evaluating Intermittent Fasting In Individuals At High Risk ForPancreatic Cancer Undergoing Screening
To learn whether an eating pattern called intermittent fasting (IF) is tolerable and feasible for individuals at high risk of pancreatic cancer and whether IF is associated with changes in biological markers, including metabolic…
- Conditions
- Evaluating, Intermittent Fasting, Pancreatic Cancer
- Trial name
- NCT07513116
- Testing
- intermittent fasting
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Acute Promyelocytic Leukemia With PML-RARA
PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
This pilot phase I trial studies how well positron emission tomography (PET)/magnetic resonance imaging (MRI), fludeoxyglucose F-18 (18F-FDG) PET/computed tomography (CT), and whole body MRI work in finding extramedullary myeloid…
- Trial name
- NCT02390635
- Testing
- Computed Tomography, Diffusion Weighted Imaging, Fludeoxyglucose F-18
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Carcinoma
Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen
This study examines the long-term effects of tamoxifen (TAM) treatment on excessive production of neutrophil extracellular traps (NET) and their impact on breast cancer and side effects.
- Trial name
- NCT05056857
- Testing
- Biospecimen Collection, Electronic Health Record Review
- Where
- United States
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloid Leukemia
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
To learn if asciminib can help to control CML. The safety and effects of this drug will also be studied.
- Trial name
- NCT06236724
- Testing
- Asciminib
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center
Philadelphia Chromosome-Positive, Acute Lymphoblastic Leukemia
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
To learn if the combination of blinatumomab and asciminib can help to control Ph+ ALL.
- Trial name
- NCT06308588
- Testing
- Blinatumomab, Asciminib
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Solid Tumors
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
This is an open label, phase 2 study investigating asciminib in patients previously treated with one line of TKI therapy.
- Trial name
- NCT06629584
- Testing
- Asciminib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Health Options, Strategic Care Planning
Communicating Health Options to Inform Care and Empower Strategic Care Planning (CHOICES): A Multi-layer Randomized Case Vignette Study.
To learn more about how the delivery of medical information affects therapy choices for participants with advanced forms of cancer.
- Trial name
- NCT06722846
- Testing
- Randomized Case Vignette Study
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- M.D. Anderson Cancer Center
Uterine Leiomyosarcoma
Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS
To find out if receiving standard chemotherapy (doxorubicin and trabectedin) can extend the cancer-free survival of patients with Stage 1b/2 uterine leiomyosarcoma who had surgery that fully removed the tumor.
- Trial name
- NCT07076186
- Testing
- Trabectedin, Doxorubicin Hydrochloride
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center